"Securing Sustainable Growth Drivers"

On June 26, Huons announced that it has completed a small-scale merger by absorbing Huons Life Science.


Huons Completes Merger with Huons Life Science...Unifies Pharmaceutical Business View original image

Huons stated, "This decision was made to integrate dispersed management resources, strengthen the competitiveness and expertise of the group's pharmaceutical business, and improve management efficiency."


Through this merger, Huons has acquired the production capacity (CAPA) for products such as solid formulations from Huons Life Science. The company plans to further strengthen its overall pharmaceutical business, including contract manufacturing organization (CMO) services.


Previously, in April, the two companies decided to merge, signed the merger agreement, and completed the necessary filings and procedures. Since Huons owned 100% of Huons Life Science prior to the merger, the merger was carried out as a small-scale merger without issuing new shares and without a capital increase.


Huons plans to improve operational efficiency by integrating its business structure into a single entity, covering everything from pharmaceutical production to management and sales. Through this, the company aims to further enhance the competitiveness of the group's pharmaceutical business and secure sustainable growth drivers in the rapidly changing global pharmaceutical market.



Huons CEO Song Sooyoung commented, "With this merger, Huons has established a foundation to bring together our core competencies in the pharmaceutical business and enhance both expertise and efficiency. We will continue to secure sustainable growth drivers in the fast-changing global pharmaceutical market by responding swiftly to changes."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing